Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-22T00:54:34.811Z Has data issue: false hasContentIssue false
  • English
  • Français

Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis

Published online by Cambridge University Press:  09 February 2017

E. Foglia ,
T. Schoeler ,
E. Klamerus ,
K. Morgan  and
S. Bhattacharyya
E. Foglia
Affiliation:
King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
T. Schoeler
Affiliation:
King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
E. Klamerus
Affiliation:
King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
K. Morgan
Affiliation:
University of Westminster, London, UK
S. Bhattacharyya*
Affiliation:
King's College London, Institute of Psychiatry, Psychology & Neuroscience, London, UK
*
*Address for correspondence: S. Bhattacharyya, Ph.D., Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE5 8AF, UK. (Email: sagnik.2.bhattacharyya@kcl.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Substance use may increase the risk of non-adherence to antipsychotics, resulting in negative outcomes in patients with psychosis.

Method

We aimed to quantitatively summarize evidence regarding the effect of cannabis use, the most commonly used illicit drug amongst those with psychosis, on adherence to antipsychotic medication. Studies were identified through a systematic database search. Adopting random-effects models, pooled odds ratios (OR) for risk of non-adherence to antipsychotic medications were calculated comparing: cannabis-users at baseline v. non-users at baseline; non users v. continued cannabis users at follow-up; non-users v. former users at follow-up; former users v. current users.

Results

Fifteen observational studies (n = 3678) were included. Increased risk of non-adherence was observed for cannabis users compared to non-users (OR 2.46, n = 3055). At follow-up, increased risk of non-adherence was observed for current users compared to non-users (OR 5.79, n = 175) and former users (OR 5.5, n = 192), while there was no difference between former users and non-users (OR 1.12, n = 187).

Conclusions

Cannabis use increases the risk of non-adherence and quitting cannabis use may help adherence to antipsychotics. Thus, cannabis use may represent a potential target for intervention to improve medication adherence in those with psychosis.

Keywords

Antipsychoticcannabis usemedication adherencepsychosis
Type
Review Article
Information
Psychological Medicine , Volume 47 , Issue 10 , July 2017 , pp. 1691 - 1705
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Addington, J, Addington, D (2007). Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatrica Scandinavia 115, 304–309.CrossRefGoogle ScholarPubMed
Barbeito, S, Vega, P, Ruiz de Azua, S, Saenz, M, Martinez-Cengotitabengoa, M, Gonzalez-Ortega, I, Bermudez, C, Hernanz, M, Corres, BF, Gonzalez-Pinto, A (2013). Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study. BMC Psychiatry 13, 326.CrossRefGoogle ScholarPubMed
Beards, S, Gayer-Anderson, C, Borges, S, Dewey, ME, Fisher, HL, Morgan, C (2013). Life events and psychosis: a review and meta-analysis. Schizophrenia Bulletin 39, 740–747.Google Scholar
Borenstein, M, Hedges, LV, Higgins, JP, Rothstein, HR (2011). Introduction to Meta-analysis. Wiley.Google Scholar
Buckley, PF (2007). Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. Journal of Clinical Psychiatry 67, 5–9.Google Scholar
Buckley, PF, Wirshing, DA, Bhushan, P, Pierre, JM, Resnick, SA, Wirshing, WC (2007). Lack of insight in schizophrenia: impact on treatment adherence. CNS Drugs 21, 129–141.CrossRefGoogle ScholarPubMed
Castberg, I, Andreas, AW, Olav, S (2009). Does level of care, sex, age, or choice of drug influence adherence to treatment with antipsychotics? Journal of Clinical Psychopharmacology 29, 415–420.Google Scholar
Coldham, E, Addington, J, Addington, D (2002). Medication adherence of individuals with a first episode of psychosis. Acta Psychiatrica Scandinavica 106, 286–290.Google Scholar
Colom, F, Vieta, E, Tacchi, MJ, Sanchez-Moreno, J, Scott, J (2005). Identifying and improving non-adherence in bipolar disorders. Bipolar Disorders 7, 24–31.Google Scholar
Conrod, P, Castellanos-Ryan, N, Strang, J (2010). Brief personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period. Archive General Psychiatry 67, 85–93.Google Scholar
Cramer, JA, Rosenheck, R (1998). Compliance with medication regimen for mental and physical disorders. Psychiatric Services 49, 196–201.CrossRefGoogle ScholarPubMed
de Haan, L, van Amelsvoort, T, Dingemans, P, Linszen, P (2007). Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up. Pharmacopsychiatry 40, 264–268.Google Scholar
DerSimonian, R, Laird, N (1986). Meta-analysis in clinical trials. Controlled Clinical Trials 7, 177–188.CrossRefGoogle ScholarPubMed
Egger, M, Davey Smith, G, Schneider, M, Minder, C (1997). Bias in meta-analysis detected by a simple, graphical test. British Medical Journal (Clinical Research Edition) 315, 629–634.CrossRefGoogle ScholarPubMed
Faridi, K, Joober, R, Malla, A (2012). Medication adherence mediates the impact of sustained cannabis use on symptom levels in first-episode psychosis. Schizophrenia Research 141, 78–82.CrossRefGoogle ScholarPubMed
Fenton, WS, Blyler, CR, Heinsse, RK (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23, 637–651.Google Scholar
Foti, DJ, Kotov, R, Guey, LT, Bromet, EJ (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry 167, 987–993.Google Scholar
Global Drug Survey (2014). (http://www.globaldrugsurvey.com/wp-content/uploads/2014/04/GDS2014_GLOBAL-COMPARISONS_EVER-BOUGHT-DRUGS-ONLINE.pdf).Google Scholar
Gonzalez-Pinto, A, Mosquera, F, Alonso, M, Lòpez, P, Ramìrez, F, Vieta, E, Baldessarini, RJ (2006). Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disorders 8, 618–624.CrossRefGoogle ScholarPubMed
Gonzalez-Pinto, A, Reed, C, Novick, D, Bertsch, J, Haro, JM (2010). Assessment of medication adherence in a cohort of patients with bipolar disorder. Pharmacopsychiatry 43, 263–270.CrossRefGoogle Scholar
Grech, A, Van Os, J, Jones, PB, Lewis, SW, Murray, RM (2005). Cannabis use and outcome of recent onset psychosis. European Psychiatry 20, 349–353.Google Scholar
Green, AI (2006). Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotoxicity Research 11, 33–39.Google Scholar
Green, B, Young, R, Kavanagh, D (2005). Cannabis use and misuse prevalence among people with psychosis. British Journal of Psychiatry 187, 306–313.CrossRefGoogle ScholarPubMed
Higashi, K, Medic, G, Littlewood, KJ, Diez, T, Granström, O, De Hert, M (2013). Medication Adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic Advances in Psychopharmacology 3, 200–218.CrossRefGoogle ScholarPubMed
Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG (2003). Measuring inconsistency in meta-analyses. British Medical Journal (Clinical Research Edition) 327, 557–560.Google Scholar
Jónsdóttir, H, Opjordsmoen, S, Birkenaes, A, Simonsen, C, Engh, J, Ringen, P, Vaskinn, A, Friis, S, Sundet, K, Andreassen, O (2013). Predictors of medication adherence in patients with schizophrenia and bipolar disorder. Acta Psychiatrica Scandinavica 127, 23–33.CrossRefGoogle ScholarPubMed
Julius, RJ, Novitsky, MA Jr., Dubin, WR (2009). Medication adherence: a review of the literature and implications for clinical practice. Journal of Psychiatric Practice 15, 34–44.Google Scholar
Kampman, O, Lehtinen, K (1999). Compliance in psychoses. Acta Psychiatrica Scandinavia 100, 167–175.Google Scholar
Keith, SJ, Kane, JM (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal of Clinical Psychiatry 64, 1308–1315.CrossRefGoogle Scholar
Koskinen, J, Lohonen, J, Koponen, H, Isohanni, M, Miettunen, J (2010). Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophrenia Bulletin 36, 1115–1130.Google Scholar
Kovasznay, B, Fleischer, J, Tanenberg-Karant, M, Jandorf, L, Miller, AD, Bromet, E (1997). Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophrenia Bulletin 23, 195–201.Google Scholar
Lacro, JP, Dunn, LB, Dolder, CR, Leckband, SG, Jeste, DV (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. Journal of Clinical Psychiatry 63, 892–909.CrossRefGoogle ScholarPubMed
Large, M, Sharma, S, Compton, MT, Slade, T, Nielssen, O (2011). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Archive General Psychiatry 68, 555–561.CrossRefGoogle ScholarPubMed
Linszen, DH, Dingemans, PM, Lenior, ME (1994). Cannabis abuse and the course of recent-onset schizophrenic disorders. Archives of General Psychiatry 51, 273–279.Google Scholar
Liraud, F, Verdoux, H (2001). Association between temperamental characteristics and medication adherence in subjects presenting with psychotic or mood disorders. Psychiatry Research 102, 91–95.Google Scholar
Martinez-Arevalo, MJ, Calcedo-Ordonez, A, Varo-Prieto, JR (1994). Cannabis consumption as a prognostic factor in schizophrenia. British Journal of Psychiatry 164, 679–681.Google Scholar
Martinez-Ortega, JM, Gutierrez-Rojas, L, Jurado, D, Higueras, A, Diaz, FJ, Gurpegui, M (2012). Factors associated with frequent psychiatric admissions in a general hospital in Spain. International Journal of Social Psychiatry 58, 532–535.Google Scholar
McGrath, J, Saha, S, Welham, J, El Saadi, O, MacCauley, C, Chant, D (2004). A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Medicine 2, 1.Google Scholar
Miller, R, Ream, G, McCormack, J, Gunduz-Bruce, H, Sevy, S, Robinson, D (2009). A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophrenia Research 113, 138–144.Google Scholar
Mojtabai, R, Lavelle, J, Gibson, PJ, Sohler, NL, Craig, TJ, Carlson, GA (2002). Gaps in Use of Antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatric Services 53, 337–339.Google Scholar
Moore, THM, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370, 319–328.Google Scholar
Mutsatsa, SH, Joyce, EM, Hutton, SB, Webb, E, Gibbins, H, Paul, S, Barnes, TR (2003). Clinical correlates of early medication adherence: west London first episode schizophrenia study. Acta Psychiatrica Scandinavia 108, 439–446.Google Scholar
Nosè, M, Barbui, C, Tansella, M (2003). How often do patients with psychosis fail to adhere to treatment programs? A systematic review. Psychological Medicine 33, 1149–1160.Google Scholar
Penttila, M, Jaaskelainen, E, Hirvonen, N, Isohanni, M, Miettunen, J (2014). Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry 205, 88–94.Google Scholar
Perkins, DO, Johnson, JL, Hamer, RM, Zipursky, RB, Keefe, RS, Centorrhino, F, Green, AI, Glick, IB, Kahn, RS, Sharma, T (2006). Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research 83, 53–63.Google Scholar
Pogge, DL, Singer, MB, Harvey, PD (2005). Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients. Journal of Child & Adolescent Psychopharmacology 15, 901–912.Google Scholar
Reed, RA, Harrow, M, Herbener, ES, Martin, EM (2002). Executive function in schizophrenia: is it linked to psychosis and poor life functioning? Journal of Nervous Mental Disorders 190, 725–732.Google Scholar
Rehman, IU, Farooq, S (2007). Schizophrenia and comorbid self reported cannabis abuse: impact on course, functioning and services use. Journal of the Pakistan Medical Association 57, 60.Google Scholar
Schimmelmann, B, Conus, P, Cotton, S, Kupferschmid, S, McGorry, P, Lambert, M (2012). Prevalence and impact of cannabis use disorders in adolescents with early onset first episode psychosis. European Psychiatry 27, 463–469.Google Scholar
Schoeler, T, Monk, A, Sami, MB, Klamerus, E, Foglia, E, Brown, R, Murray, R, Camuri, G, Altamura, AC, Murray, R, Bhattacharyya, S (2016 a). Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3, 215–225.Google Scholar
Schoeler, T, Petros, N, Di Forti, M, Pingault, JB, Klamerus, E, Foglia, E, Small, A, Murray, R, Bhattacharyya, S (2016 b). Association between continued cannabis use and risk of relapse in first-episode psychosis: a quasi-experimental investigation within an observational study. JAMA Psychiatry 73, 1173–1179.Google Scholar
Sendt, KV, Tracy, DK, Bhattacharyya, S (2014). A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Research 225, 14–30.Google Scholar
Sharma, T, Antonova, L (2003). Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatric Clinicas of North America 26, 25–40.Google Scholar
Strakowski, SM, DelBello, MP, Fleck, DE, Adler, CM, Anthenelli, RM, Keck, PE, Arnold, LM, Amicone, J (2007). Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry 64, 57–64.Google Scholar
Stroup, DF, Berlin, JA, Morton, SC, Olkin, I, Williamson, GD, Rennie, D, Moher, D, Becker, BJ, Sipe, TA, Thacker, SB (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Journal of the American Medical Association 283, 2008–2012.Google Scholar
Swann, AC, Dougherty, DM, Pazzaglia, PJ, Pham, M, Moeller, FG (2004). Impulsivity: a link between bipolar disorder and substance abuse. Bipolar Disorders 6, 204–212.Google Scholar
Van Dijk, D, Koeter, MWJ, Hijman, R, Kahn, RS, van den Brink, W (2012). Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophrenia Research 37, 50–57.CrossRefGoogle Scholar
Velligan, DI, Lam, YW, Glahn, DC, Barrett, JA, Maples, NJ, Ereshefsky, L, Miller, AL (2006). Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bulletin 32, 724–742.Google Scholar
Wilson, RP, Bhattacharyya, S (2016). Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: a systematic review. Journal of Psychopharmacology 30, 99–111.Google Scholar
Zammit, S, Moore, THM, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M (2008). Effects of cannabis use on outcomes of psychotic disorders: systematic review. British Journal of Psychiatry 193, 357–363.Google Scholar
Supplementary material: File

Foglia supplementary material

Foglia supplementary material 1

Download Foglia supplementary material(File)
File 130 KB